Solid Biosciences Inc
SLDB6.963USD
+0.133+1.94%
Market hours （ET）Quotes delayed by 15 min
539.57MMarket Cap
LossP/E TTM
More Details of Solid Biosciences Inc Company
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Company Info
Ticker SymbolSLDB
Company nameSolid Biosciences Inc
IPO dateJan 26, 2018
CEOMr. Alexander (Bo) Cumbo
Number of employees100
Security typeOrdinary Share
Fiscal year-endJan 26
Address500 Rutherford Avenue
CityCHARLESTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02129
Phone16173374680
Websitehttps://www.solidbio.com/
Ticker SymbolSLDB
IPO dateJan 26, 2018
CEOMr. Alexander (Bo) Cumbo
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
132.92K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
122.12K
+3.89%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.72K
--
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
24.79K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
19.28K
+35.45%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
13.23K
+51.52%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+169.09%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
132.92K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
122.12K
+3.89%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.72K
--
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
24.79K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
19.28K
+35.45%
Revenue Breakdown
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
15.36%
Bain Capital Life Sciences Investors, LLC
10.21%
Invus Public Equities Advisors, LLC
9.57%
Adage Capital Management, L.P.
8.68%
Commodore Capital LP
7.51%
Other
48.67%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
15.36%
Bain Capital Life Sciences Investors, LLC
10.21%
Invus Public Equities Advisors, LLC
9.57%
Adage Capital Management, L.P.
8.68%
Commodore Capital LP
7.51%
Other
48.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor
32.52%
Hedge Fund
31.63%
Private Equity
15.36%
Investment Advisor/Hedge Fund
13.19%
Venture Capital
8.97%
Research Firm
0.87%
Individual Investor
0.56%
Bank and Trust
0.04%
Family Office
0.01%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
235
79.94M
103.13%
+26.28M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
2023Q2
203
16.54M
84.41%
-1.08M
2023Q1
234
16.00M
82.14%
-1.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
11.91M
15.36%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.21%
+2.88M
+57.15%
Mar 31, 2025
Invus Public Equities Advisors, LLC
7.42M
9.57%
+3.67M
+97.81%
Mar 31, 2025
Adage Capital Management, L.P.
6.73M
8.68%
+4.98M
+284.96%
Mar 31, 2025
Commodore Capital LP
5.83M
7.51%
--
--
Mar 31, 2025
RA Capital Management, LP
4.33M
5.59%
+90.74K
+2.14%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.52M
4.54%
+3.47M
+7432.14%
Mar 31, 2025
VR Adviser, LLC
2.48M
3.2%
+2.48M
--
Mar 31, 2025
The Vanguard Group, Inc.
2.46M
3.17%
+1.06M
+75.59%
Mar 31, 2025
Redmile Group, LLC
2.02M
2.6%
+1.40M
+228.19%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.67%
Tema Neuroscience and Mental Health ETF
0.29%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.67%
Tema Neuroscience and Mental Health ETF
Proportion0.29%
iShares Micro-Cap ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Date
Type
Ratio
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
